Chuck Royce's position in Palvella Therapeutics is currently worth $3.62M. That's 0.03% of their equity portfolio (507th largest holding). The first Palvella Therapeutics trade was made in Q1 2025. Since then Chuck Royce bought shares two more times and sold shares on two occasions. The stake costed the investor $1.53M, netting the investor a gain of 137% so far.